CGTLive’s Weekly Rewind – October 28, 2022

Article

Review top news and interview highlights from the week ending October 28, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Cystinosis Gene Therapy Trial in Full Swing

The trial is being conducted at the University of California – San Diego under the leadership of Stephanie Cherqui, PhD.

2. TJ Cradick, PhD, on A Potential Cure for HIV With EBT-101

The chief scientific officer of Excision BioTherapeutics discussed the phase 1/2 clinical trial of the CRISPR gene editing therapy.

3. PR001 Hopes to Address Underlying Mutations in Neuronopathic Type 2 Gaucher Disease

CGTLive highlights the PROVIDE trial of PR001 for Gaucher Awareness Month.

4. Aimee Donald, MBChB, PhD, on Assessing PR001 in Children With Type 2 Gaucher Disease

The pediatrician from Royal Manchester Children’s Hospital discussed progress with the PROVIDE trial of PR001.

5. JC Virus T-Cell Therapy to be Evaluated in Progressive Multifocal Leukoencephalopathy

The trial expects to enroll its first patient in the first half of 2023.

Recent Videos
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
© 2024 MJH Life Sciences

All rights reserved.